Who is sponsoring NCT04073745?

NCT04073745 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT04073745?

Interventions in NCT04073745: Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy.

What condition does NCT04073745 study?

NCT04073745 studies Lung Non-Small Cell Carcinoma, Positive Surgical Margin, Resected Mass, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8.

Is NCT04073745 still recruiting?

NCT04073745 is currently active, enrolled. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT04073745

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

Active, enrolled Phase 1 Last updated 4 February 2026

What this trial tests

Phase 1 trial testing Quality-of-Life Assessment in Lung Non-Small Cell Carcinoma in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

4 December 2019

Primary endpoint
11 August 2025

31 March 2026

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	4 December 2019
Primary completion	11 August 2025
Estimated completion	31 March 2026
Sites	1 location across United States

Drugs / interventions tested

Quality-of-Life Assessment
Questionnaire Administration
Stereotactic Body Radiation Therapy — full drug profile →

Conditions studied

Lung Non-Small Cell Carcinoma — all drugs for Lung Non-Small Cell Carcinoma →
Positive Surgical Margin — all drugs for Positive Surgical Margin →
Resected Mass — all drugs for Resected Mass →
Stage III Lung Cancer AJCC v8 — all drugs for Stage III Lung Cancer AJCC v8 →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Lung Non-Small Cell Carcinoma or Positive Surgical Margin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies the side effects of single fraction stereotactic body radiation therapy after surgery in treating patients with non-small cell lung cancer. Standard radiation for lung cancer involves delivering small doses of daily radiation for several weeks. However, this technique has resulted in inferior outcomes compared to surgery and is associated with damage to surrounding normal lung. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving stereotactic body radiation therapy in fewer treatment sessions (single fraction) may kill tumor cells and cause less damage to normal tissue.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story.
Serrano J, Crespo PC, Taboada B, Gonzalez AA, et al · · 2021 · cited 6× · PMID 34733608 · DOI 10.5306/wjco.v12.i10.833
Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer.
Kim BH, Kim JS, Kim HJ. · · 2023 · cited 3× · PMID 37793623 · DOI 10.3857/roj.2023.00430

Verify or expand the search:

Other trials of Quality-of-Life Assessment

Trials testing the same drug.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT06710418 — Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi · NA · recruiting
NCT06500481 — Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- · Phase 3 · recruiting
NCT05539365 — Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast · Phase 2 · withdrawn
NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting

Other recruiting trials for Lung Non-Small Cell Carcinoma

Currently open trials in the same condition.

NCT07216404 — Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer · Phase 2 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07339254 — Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study · recruiting
NCT06983899 — Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell · NA · recruiting
NCT07186699 — Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD · recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04073745 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04073745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing